NIOX Group Joins Growth Index on High-Return Financials and Steady Respiratory Diagnostics Growth

NIOX Group sells devices and consumables that measure fractional exhaled nitric oxide, a biomarker used in clinics and doctor's offices to guide asthma diagnosis and treatment. The model is largely recurring: the hardware places devices into practices, and repeat consumable sales follow. That structure shows up in the numbers, with gross margins at 69% and an operating margin that has reached 22%.

The financials score of 83 is the highest across the six dimensions and is the clearest reason for the addition. A 29.8% return on invested capital alongside a net-cash position of $19M means the company is generating well above its cost of capital without relying on leverage. Revenue has grown at a 15.3% five-year CAGR, and while the per-share rate of 12.8% is modestly lower, the gap suggests limited dilution rather than a structural problem.

The runway score of 64 reflects that respiratory diagnostics is a real but bounded market. Asthma affects hundreds of millions of people globally, yet FeNO testing remains underpenetrated in primary care settings in most geographies, which leaves room for the installed base to grow. A growth score of 74 suggests the engine is working, though the risks score of 59 is the weakest dimension and likely captures reimbursement uncertainty and dependence on clinical adoption rates varying by country.

What to watch: whether operating margins hold or expand as the consumable base grows, the pace of new device placements in underpenetrated markets such as the US and Asia, and any changes to reimbursement policy for FeNO testing, which remains the single biggest lever on the addressable market.